Align Technology, Inc.

Align Technology, Inc. (ALGN) Market Cap

Align Technology, Inc. has a market capitalization of .

No quote data available.

CEO: Joseph Hogan

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2001-01-30

Website: https://www.aligntech.com

Align Technology, Inc. (ALGN) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Analyst Sentiment

73%
Strong Buy

From 16 Active Polls

1Y Forecast: $203.60

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$185

Median

$200

High Bound

$235

Average

$204

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$203.60
▲ +21.38% Upside
Low Target
$185.00
10% Risk
Median Target
$200.00
19% Mid
High Target
$235.00
40% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALIGN TECHNOLOGY INC (ALGN) — Investment Overview

🧩 Business Model Overview

ALIGN TECHNOLOGY INC operates in an integrated, digital orthodontics workflow. Dental professionals (orthodontists and other prescribing clinicians) acquire patient records, scan or capture 3D information using ALIGN’s imaging ecosystem, and then receive treatment plans and manufacturing fulfillment for clear aligner therapy. The economic flow is tied to per-case treatment delivery, with recurring elements coming from ongoing clinical use of the imaging platform and ancillary components that support continued treatment refinement and retention.

The core “stickiness” is structural: ALIGN’s system is not only a product (aligners), but a tightly coupled software-and-manufacturing process that clinicians and patients experience as one treatment pathway—from capture to plan to production—creating practical friction to switch to alternative platforms once a practice has standardized its workflow.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by case-based aligner therapy, including initial aligners and supporting components used throughout a treatment course. A second pillar comes from digital imaging and related offerings that enable clinics to capture accurate 3D records and support treatment planning.

Margin drivers are typically a function of:

  • Manufacturing scale and process yield: aligner production benefits from standardized workflows, centralized production, and continuous process optimization.
  • Product mix: higher-complexity treatments generally command higher economics per patient course versus entry-level cases.
  • Workflow digitization: tighter integration between imaging capture and manufacturing planning reduces rework and improves case throughput.
  • Installed base monetisation (imaging ecosystem): clinics using ALIGN’s imaging infrastructure tend to generate repeat demand for software-enabled capture and service components tied to ongoing clinical operations.

🧠 Competitive Advantages & Market Positioning

ALIGN’s competitive advantages center on a digital orthodontic ecosystem that creates switching costs and an embedded clinical workflow.

  • High Switching Costs (Workflow + Case Data)
    Once a practice standardizes on ALIGN’s scanning, planning, and manufacturing process, changing suppliers can require workflow redesign, staff training, and a re-architecture of how patient records are captured and transmitted. Treatment planning processes and clinician familiarity raise the cost of switching for both providers and—indirectly—patients.
  • Intangible Asset: Clinical Protocol & Software Integration
    ALIGN benefits from accumulated know-how embedded in its treatment planning approach, digital workflow, and manufacturing execution—an asset that is difficult to replicate quickly because it spans both technology and clinical operations.
  • Cost Advantages Through Digitized Scale
    Digitization supports more consistent manufacturing outputs and reduces inefficiency versus less standardized approaches.

Competitive benchmarking (clear aligners and digital orthodontics):

  • Dentsply Sirona (e.g., SureSmile-enabled clear aligner workflows): strong presence in dental technology; competes on digital orthodontic tooling and treatment planning capabilities.
  • Straumann (e.g., ClearCorrect and aligner-adjacent offerings): competes via established brand footprint and orthodontic product breadth.
  • GC Orthodontics (clear aligner systems and related orthodontic solutions): competes on product offerings and clinician channel relationships.

Compared with these rivals, ALIGN is positioned as a more tightly integrated end-to-end ecosystem spanning imaging capture, digital treatment planning, and aligner manufacturing execution—raising practical barriers to switching for practices that have standardized on the full workflow.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular penetration of clear aligners and broader adoption of digital orthodontic workflows:

  • TAM expansion via treatment penetration: clear aligners broaden the addressable market by improving cosmetic acceptance versus traditional braces, expanding adoption beyond only the most price-insensitive or most conventionally aligned patient segments.
  • Digital workflow adoption: clinics increasingly choose digital records and treatment planning because it improves precision, reduces operational friction, and supports scalable case management.
  • Practice conversion: the installed base of clinicians using digital capture and planning tools tends to expand use depth as staff training, referral patterns, and operational familiarity accumulate.
  • International growth: orthodontic modernization and rising digital adoption continue to create incremental opportunities for clear aligners and imaging ecosystems in underpenetrated markets.

ALIGN’s structural position is that each incremental case delivered reinforces the clinic’s established workflow, supporting long-run share durability even when competitors offer comparable aligner products.

⚠ Risk Factors to Monitor

  • Competitive technology and pricing pressure: competitors can narrow differentiation through improved software, manufacturing capabilities, and promotional pricing—potentially affecting mix and economics per case.
  • Regulatory and clinical safety oversight: orthodontics involves medical-device and treatment-protocol scrutiny. Changes in regulatory expectations or guidance can impact workflows, documentation, and commercialization economics.
  • Channel concentration and adoption friction: ALIGN depends on practitioner adoption and standardized workflows; shifts in clinician preferences or reimbursement dynamics can slow conversion.
  • Manufacturing capacity and operational execution: scaling production while maintaining quality across varied case complexity creates execution risk.
  • Technological disruption: advances in imaging, new aligner materials, or fundamentally different treatment modalities could reduce the relative advantage of existing workflow integrations.

📊 Valuation & Market View

Valuation for digital orthodontics businesses typically reflects a combination of:

  • Growth durability (case adoption, practice conversion, international penetration),
  • Gross margin trajectory driven by scale, yield, and product mix, and
  • Operating leverage as the installed base and workflow ecosystem mature.

Market participants often anchor to revenue-based multiples (e.g., EV/Sales) given the category’s growth-orientation, but the most material swing factors generally relate to sustainable case volume, mix improvement, and evidence of high-quality cash generation once scale effects mature.

🔍 Investment Takeaway

ALIGN TECHNOLOGY INC offers an ecosystem-based competitive position in clear aligners and digital orthodontics. The principal investment thesis rests on workflow-driven switching costs, cumulative clinical-software know-how, and digitized scale economics that together support durable practitioner adoption. While competitive dynamics and clinical/regulatory oversight remain meaningful risks, ALIGN’s integrated platform model is structurally harder to displace than a standalone aligner product supplier.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ALGN reported Q1’26 revenue of $1.040B and net income of $112.8M (EPS $1.58). On a YoY basis, revenue rose +6.2% (from $979.3M in Q1’25) and net income increased +20.9% (from $93.2M). QoQ, revenue slipped -0.7% versus Q4’25 ($1.048B), while net income declined -16.9% ($135.8M in Q4’25). Profitability improved over the year: gross margin expanded to 70.8% from 69.5% in Q1’25, and net margin rose to 10.8% from 9.5%. Sequentially, margins contracted modestly—net margin fell from 13.0% in Q4’25 to 10.8% in Q1’26—suggesting cost/mix pressure in the quarter. Operating income was $142.0M (operating margin 13.6%), down from 15.2% in Q4’25. Cash flow remained positive, with operating cash flow of $151.0M and free cash flow of $151.0M in Q1’26. The company paid no dividends; instead it used cash for repurchases historically, though none were reported in this quarter. Balance sheet resilience is strong: equity is $4.149B and net debt is negative (net cash position) at -$976M. Shareholder returns: marketPerformance shows +13.7% over 1 year and +46.4% over 6 months, supporting a positive but not momentum-superior (20%+) backdrop. Analyst consensus target is $203.6 vs. ~$190 current (moderate upside)."

Revenue Growth

Positive

YoY revenue growth of +6.2% in Q1’26, with mild QoQ deceleration (-0.7% vs Q4’25).

Profitability

Positive

Gross and net margins expanded YoY (net margin +1.3pp to 10.8%), but sequentially net margin contracted from 13.0% (Q4’25), indicating some quarter-to-quarter pressure.

Cash Flow Quality

Positive

Q1’26 operating cash flow of $151.0M and free cash flow $151.0M with no dividends. Cash generation remains solid despite lower QoQ net income.

Leverage & Balance Sheet

Strong

Strong balance sheet with $4.149B equity and a net cash position (net debt -$976M). Assets and equity remain resilient over the last few quarters.

Shareholder Returns

Neutral

Positive price performance (+13.7% 1Y, +46.4% 6M) but below the >20% 1Y momentum threshold; no dividend yield reported.

Analyst Sentiment & Valuation

Neutral

Consensus price target $203.6 vs. ~$190 implies moderate upside; valuation appears elevated on earnings/FCF multiples.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

ALGN delivered another upside quarter driven by Clear Aligner execution rather than one-off items: record shipments (686k cases, +6.7% YoY) came with higher utilization and submitters, supporting Clear Aligner revenue of $856M (+7.4% YoY). Profitability improved meaningfully versus last year (GAAP gross margin +140 bps; GAAP operating margin +30 bps; non-GAAP operating margin +250 bps), with a major tax benefit (GAAP effective tax rate 24.3% vs 33.6% prior-year). Systems & Services was steady to flat (up 0.9% YoY) with FX support but seasonal sequential softness. Management’s key operational focus is scaling value/configuration products (0-additional aligners, DSP touch-up) and affordability/financing tools (HFD in 4,000+ offices; APAC DSP launch in Q2). The main near-term risk is Middle East-driven demand uncertainty; Q2 guidance assumes some impact, but Q1 EMEA was immaterial and iTero reported no production/shipment disruption.

AI IconGrowth Catalysts

  • Record Clear Aligner shipments: 686,000 cases (+6.7% YoY), driven by submitter expansion (+3% YoY; +3,000 orthodontists/GPs) and utilization (+3.4% YoY)
  • Invisalign adoption strength across age groups and geographies: adults treated 449,000 (+7.8% YoY); teens/growing kids 237,000 (+4.8% YoY) led by China and Latin America
  • DSO momentum: DSO Clear Aligner volumes grew double digit and represented ~1/4 of total global volumes; benefits from iTero scanner utilization and Align digital platform fit with DSO operating models
  • Expansion of affordability/conversion levers: Invisalign First, Invisalign Pal expander (IPE), and mandibular advancement with occlusal blocks
  • Doctor Subscription Program (DSP) traction: DSP touch-up cases growing double digit YoY; North America supported early momentum; APAC expected launch in Q2 2026
  • Patient financing scaling: Healthcare Financial Direct (HFD) live in 4,000+ US offices; strong adoption in American Academy of Clear Aligners (AACA) practices
  • Invisalign ART expansion: inaugural ART pilot success in EMEA; Invisalign ART pilot begun in the United States with labs and doctors (training in several markets); integrates with exocad

Business Development

  • Invisalign ART pilot (US): labs and doctors beginning training in several markets; ART integrates with exocad for treatment planning within the exocad environment
  • AACA practice adoption: strong US HFD adoption among American Academy of Clear Aligners member practices
  • Peer-to-peer mentoring program Connect Doctors: active across all regions (12-month structured clinician-to-clinician mentoring)

AI IconFinancial Highlights

  • Revenue: $1.041B (+6.2% YoY); constant currency +$44.9M (+4.5%)
  • Clear Aligner revenue: $856M (+7.4% YoY); impacted by higher volume, favorable FX (~$38.2M; ~+4.7%), and lower net deferrals; partially offset by higher discounts and lower-priced mix
  • Systems & Services revenue: $184.1M (+0.9% YoY); FX favorable (~+$6.7M; ~+3.8%); sequential decline attributed to seasonal capital equipment pattern
  • Gross margin: GAAP 70.8% (+1.4 pts YoY); non-GAAP 71.8% (+1.6 pts YoY). Clear Aligner gross margin 71.6% (+1.1 pts YoY). FX unfavorably impacted overall gross margin by ~0.4 pts
  • Operating margin: GAAP 13.6% (+0.3 pts YoY); non-GAAP 21.5% (+2.5 pts YoY). FX unfavorably impacted operating margin by ~0.1 pts
  • Tax: GAAP effective tax rate 24.3% vs 33.6% in Q1 2025; non-GAAP effective tax rate 20% (reflecting long-term projected tax rate)
  • EPS: GAAP diluted EPS $1.57 (+$0.31 YoY); non-GAAP EPS $2.58 (+21% YoY)

AI IconCapital Funding

  • Repurchases completed: $200M plan completed by end of Jan 2026 (between Aug 2025-Jan 2026), ~1.4M shares at avg $143.85
  • Remaining authorization (as of Mar 31, 2026): $800M available under prior $1B program
  • Incremental repurchase announced: up to an additional $200M over ~6 months beginning on/around May 1, 2026
  • Balance sheet: cash & cash equivalents $1,059.8M (up $186.8M YoY); OCF $151M; capex $30.8M; free cash flow $120.3M
  • Working capital: Q1 accounts receivable $1.1251B; days sales outstanding 97 days (flat YoY)

AI IconStrategy & Ops

  • Margin expansion drivers called out: lower refinement rates, improved treatment predictability, and higher manufacturing throughput benefits scaling with volume/data
  • Configuration/product mix shift: scaling 0-additional-aligner configurations and streamlined options with limited/no additional aligners to reduce/avoid revenue deferral and improve cash conversion
  • Product rollout: COMP Zero AA expanded building from prior DSO pilot (U.S. DSOs in retail Q1); management anticipates expanding over the year due to DSO partner adoption signals
  • Affordability bundles: lower-priced configurations such as COMP 3in3 and DSP Touch-Up referenced as supporting gross margin and cash conversion via fewer/no additional aligners
  • Technology/digital scaling: >12M iTero digital scans in Q1; installed base of active scanners exceeded 125,000 globally
  • Direct printing: limited market releases of direct 3D-printed attachments/retainers in Q1; management plans further updates as programs progress (phased, quality/reliability focused)

AI IconMarket Outlook

  • Q2 2026 worldwide revenues: $1.040B to $1.06B (+~3% to +5% YoY)
  • Q2 Clear Aligner: volume expected up sequentially and YoY; average selling price expected flat sequentially and YoY
  • Q2 Systems & Services: expected up sequentially
  • FY 2026: reaffirmed revenue growth +3% to +4% YoY
  • FY 2026 margin targets: GAAP operating margin ~slightly below 18%; non-GAAP operating margin ~23.7% (non-GAAP +~100 bps YoY); FY guidance basis assumes FX moderation toward ~100 bps remaining-quarter impact
  • FX assumption: impact expected to moderate in remaining quarters, trending toward full-year assumption of approximately 100 basis points
  • FY 2026 capex: $125M to $150M

AI IconRisks & Headwinds

  • Middle East military action uncertainty: management assumes some impact in Q2 on both Clear Aligner and scanner demand due to potential patient traffic/consumer demand/shipping-freight effects; EMEA impact was immaterial in Q1 but expected more in Q2 and beyond under uncertainty
  • FX volatility and potential adverse foreign exchange fluctuation
  • Potential tariff/duty or other fee changes: guidance explicitly assumes no changes beyond currently applicable duties/tariffs/fees
  • Retail channel softness signals: retail mixed with reported less patient traffic in the U.S. during the quarter

Q&A: Analyst Interest

  • Topic: Q2 and 2H profitability/cadence assumptions; Middle East quantified impact. Management tied profitability strength to prior year restructuring taking hold (COGS and OpEx) and expects continued productivity as volume increases; Middle East was not quantified in bps/% but guided as assumed impact in Q2 and beyond based on uncertainty.
  • Topic: Confirming Middle East impact level and whether iTero manufacturing/shipping was disrupted; plus April trend help. Management stated Middle East impact sits in the single digits within the company’s reporting and said there was minimal impact in March with reflection in Q2 and beyond; iTero reported no disruption from production/shipment.
  • Topic: Share repurchase timing vs conflict transience and cash levels. Management emphasized conviction shares remain attractively valued and supported by improving fundamentals; additionally, disclosed prudence in guidance and capital return discipline, opting to start the next $200M repurchase cycle around May 1 rather than accelerate through full $800M earlier.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ALGN Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Align Technology, Inc. (ALGN) Financial Profile